Ginsburg, Diane

Diane Ginsburg, a sole proprietor based in Austin, Texas, provides expert witness and pharmaceutical consulting services to the Drug Enforcement Administration as a full-and-open prime contractor, with no subcontracting footprint. Ginsburg holds a Doctor of Pharmacy degree and operates under NAICS 541990 (All Other Professional, Scientific, and Technical Services) and PSC R424 (Support — Professional: Expert Witness), delivering specialized support for federal drug diversion investigations and regulatory compliance matters.

Ginsburg's customer base is entirely concentrated within the Department of Justice. The DEA accounts for 31 of 34 recent awards (94% of potential value at $254 thousand), with the DOJ Criminal Division and US Attorney's Offices rounding out two additional orders. The portfolio is entirely prime work — no subcontracting activity appears across the award history.

Work scope centers on prescription drug diversion investigations and expert testimony. Representative awards include a $18,750 purchase order from DEA (September 2026) for pharmaceutical expert review, affidavit preparation, and administrative hearing support through August 2027; a $18,750 order (July 2025) for report preparation, revision, and expert testimony on an active investigation (estimated 75 hours, priced at labor-hours); a $15,600 order (August 2025) for continued subject matter expert and expert witness services; and a $5,000 order (May 2023) for expert review of patient records and prescription monitoring program data. Individual contract values range from $1,500 to $18,750, with pricing consistently structured on a labor-hours basis at hourly rates around $250 per hour. Work is performed in Austin, Texas and Metairie, Louisiana.

Activity has been episodic. The portfolio shows nine awards in 2021, then dropped to one in 2022, three in 2023, none in 2024, three in 2025, and one in 2026 — a pattern suggesting task-order work on an intermittent, case-by-case basis rather than continuous engagement. Three awards (combined potential value $40 thousand) reach ultimate completion inside the next twenty-four months. Across the entire footprint dating to 2011, Ginsburg has received over thirty DEA expert witness contracts, with combined potential value of $256 thousand and an obligation rate of 94%, indicating reliable execution and repeat customer relationship with DEA's pharmaceutical enforcement and prosecution program.